|
WO2020123395A1
(en)
|
2018-12-10 |
2020-06-18 |
Ideaya Biosciences, Inc. |
2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
|
|
LT3902803T
(lt)
|
2018-12-27 |
2023-04-25 |
Les Laboratoires Servier |
Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui
|
|
EA202191800A1
(ru)
*
|
2018-12-27 |
2021-09-13 |
Ле Лаборатуар Сервье Сас |
Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
|
|
SG11202112952SA
(en)
*
|
2019-05-31 |
2021-12-30 |
Servier Lab |
Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
|
|
US20230227409A1
(en)
*
|
2020-06-10 |
2023-07-20 |
Ideaya Biosciences, Inc. |
Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
|
|
WO2021252680A1
(en)
*
|
2020-06-10 |
2021-12-16 |
Ideaya Biosciences, Inc. |
4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
|
|
EP4165040B1
(en)
*
|
2020-06-10 |
2025-08-27 |
Ideaya Biosciences, Inc. |
2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors
|
|
US20240208965A1
(en)
*
|
2020-06-10 |
2024-06-27 |
Ideaya Biosciences, Inc. |
Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
|
|
CN115960098B
(zh)
*
|
2020-09-11 |
2026-04-10 |
上海凌达生物医药有限公司 |
一类含氮稠环类化合物的制备方法和用途
|
|
CN115916778B
(zh)
*
|
2020-09-12 |
2026-03-20 |
赛诺哈勃药业（成都）有限公司 |
甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
|
|
WO2022063128A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
上海凌达生物医药有限公司 |
一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
|
|
CN114507231B
(zh)
*
|
2020-11-17 |
2025-06-03 |
南京再明医药有限公司 |
内酰胺类化合物及其制备方法
|
|
CN114634521A
(zh)
*
|
2020-12-15 |
2022-06-17 |
首药控股(北京)股份有限公司 |
Dna-pk选择性抑制剂及其制备方法和用途
|
|
US20240124454A1
(en)
*
|
2020-12-31 |
2024-04-18 |
Nanjing Zaiming Pharmaceutical Co., Ltd. |
Tricyclic compound and use thereof
|
|
WO2022206730A1
(zh)
*
|
2021-03-29 |
2022-10-06 |
武汉人福创新药物研发中心有限公司 |
嘧啶并吡嗪酮化合物及其用途
|
|
WO2022222911A1
(zh)
*
|
2021-04-19 |
2022-10-27 |
武汉人福创新药物研发中心有限公司 |
嘧啶酮化合物及其用途
|
|
CN117412967A
(zh)
*
|
2021-06-02 |
2024-01-16 |
南京正大天晴制药有限公司 |
蛋氨酸腺苷转移酶2a抑制剂
|
|
AR127404A1
(es)
|
2021-10-20 |
2024-01-17 |
Insilico Medicine Ip Ltd |
Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
|
|
CN118265700A
(zh)
*
|
2021-11-09 |
2024-06-28 |
上海海雁医药科技有限公司 |
取代的萘啶酮衍生物、其药物组合物及应用
|
|
CN114028572B
(zh)
*
|
2021-11-30 |
2022-11-25 |
清华大学 |
Mat2a抑制剂用于治疗哮喘的新应用
|
|
CN118414338A
(zh)
*
|
2021-12-21 |
2024-07-30 |
南京正大天晴制药有限公司 |
蛋氨酸腺苷转移酶2a的杂环抑制剂
|
|
WO2023125737A1
(en)
*
|
2021-12-29 |
2023-07-06 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds and use thereof
|
|
JP2025503186A
(ja)
*
|
2022-01-26 |
2025-01-30 |
勤浩医▲葯▼（▲蘇▼州）有限公司 |
Ｍｔａｐ欠失型がん治療用メチオニンアデノシルトランスフェラーゼ２ａ阻害剤
|
|
WO2023169554A1
(zh)
*
|
2022-03-11 |
2023-09-14 |
赛诺哈勃药业（成都）有限公司 |
甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
|
|
JP2025521737A
(ja)
|
2022-06-27 |
2025-07-10 |
石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 |
三環式化合物およびその使用
|
|
CN117430596A
(zh)
*
|
2022-07-13 |
2024-01-23 |
上海海和药物研究开发股份有限公司 |
二并环类mat2a抑制剂及其用途
|
|
AU2023361063A1
(en)
|
2022-10-13 |
2025-04-17 |
Hanmi Pharm. Co., Ltd. |
Novel tricyclic derivative compound and uses thereof
|
|
CN121241050A
(zh)
*
|
2023-03-06 |
2025-12-30 |
甘李药业股份有限公司 |
一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
AU2024302736C1
(en)
*
|
2023-06-14 |
2026-01-29 |
Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. |
Crystal form of methionine adenosyltransferase 2a heterocyclic inhibitor, preparation method therefor, and use thereof
|
|
WO2025000265A1
(en)
*
|
2023-06-28 |
2025-01-02 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds usefull as sos1 inhibitor
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2025088571A1
(en)
*
|
2023-10-26 |
2025-05-01 |
Astrazeneca Ab |
Crystalline forms of tead inhibitor
|
|
CN117567473B
(zh)
*
|
2023-11-09 |
2025-07-04 |
中国药科大学 |
一种靶向同源二聚体的抑制剂及其制备方法与应用
|
|
WO2025166260A1
(en)
|
2024-02-02 |
2025-08-07 |
Ideaya Biosciences, Inc. |
Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
|
|
WO2025166274A1
(en)
|
2024-02-02 |
2025-08-07 |
Ideaya Biosciences, Inc. |
Tricyclic guanidino compounds as prmt5 inhibitors
|
|
WO2025166257A1
(en)
|
2024-02-02 |
2025-08-07 |
Ideaya Biosciences, Inc. |
Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
|
|
WO2025166215A1
(en)
|
2024-02-02 |
2025-08-07 |
Ideaya Biosciences, Inc. |
Triheterocyclic guanidino compounds as prmt5 inhibitors
|
|
WO2025166229A1
(en)
|
2024-02-02 |
2025-08-07 |
Ideaya Biosciences, Inc. |
Tricyclic amidino compounds as prmt5 inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|